Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 417

1.

Identification of clinically-relevant dysglycemia phenotypes based on continuous glucose monitoring data from youth with type 1 diabetes and elevated hemoglobin A1c.

Kahkoska AR, Adair LA, Aiello AE, Burger KS, Buse JB, Crandell J, Maahs DM, Nguyen CT, Kosorok MR, Mayer-Davis EJ.

Pediatr Diabetes. 2019 Apr 10. doi: 10.1111/pedi.12856. [Epub ahead of print]

PMID:
30972889
2.

Correction to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB.

Diabetologia. 2019 May;62(5):873. doi: 10.1007/s00125-019-4845-x.

PMID:
30899969
3.

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.

Verma S, Bain SC, Monk Fries T, Mazer CD, Nauck MA, Pratley RE, Rasmussen S, Saevereid HA, Zinman B, Buse JB.

Diabetes Obes Metab. 2019 Mar 9. doi: 10.1111/dom.13698. [Epub ahead of print]

PMID:
30851070
4.

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).

Pratley RE, Emerson SS, Franek E, Gilbert MP, Marso SP, McGuire DK, Pieber TR, Zinman B, Hansen CT, Hansen MV, Mark T, Moses AC, Buse JB; DEVOTE Study Group.

Diabetes Obes Metab. 2019 Mar 8. doi: 10.1111/dom.13699. [Epub ahead of print]

PMID:
30850995
5.

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.

Danne T, Cariou B, Buse JB, Garg SK, Rosenstock J, Banks P, Kushner JA, McGuire DK, Peters AL, Sawhney S, Strumph P.

Diabetes Care. 2019 Mar 4. pii: dc182149. doi: 10.2337/dc18-2149. [Epub ahead of print]

PMID:
30833371
6.

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).

Brown-Frandsen K, Emerson SS, McGuire DK, Pieber TR, Poulter NR, Pratley RE, Zinman B, Ranthe MF, Grøn R, Lange M, Moses AC, Örsy P, Buse JB; DEVOTE Study Group.

Diabetes Obes Metab. 2019 Feb 22. doi: 10.1111/dom.13677. [Epub ahead of print]

PMID:
30793465
7.

Identifying individual risk rare variants using protein structure guided local tests (POINT).

Marceau West R, Lu W, Rotroff DM, Kuenemann MA, Chang SM, Wu MC, Wagner MJ, Buse JB, Motsinger-Reif AA, Fourches D, Tzeng JY.

PLoS Comput Biol. 2019 Feb 19;15(2):e1006722. doi: 10.1371/journal.pcbi.1006722. eCollection 2019 Feb.

8.

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors.

Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M.

Diabetes Care. 2019 Feb 6. pii: dc182316. doi: 10.2337/dc18-2316. [Epub ahead of print]

PMID:
30728224
9.

Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers.

Yang JY, Wang T, Pate V, Gower EW, Crowley MJ, Buse JB, Stürmer T.

Diabetes Obes Metab. 2019 May;21(5):1223-1236. doi: 10.1111/dom.13647. Epub 2019 Mar 4.

PMID:
30697897
10.

Performance of a computable phenotype for identification of patients with diabetes within PCORnet: The Patient-Centered Clinical Research Network.

Wiese AD, Roumie CL, Buse JB, Guzman H, Bradford R, Zalimeni E, Knoepp P, Morris HL, Donahoo WT, Fanous N, Epstein BF, Katalenich BL, Ayala SG, Cook MM, Worley KJ, Bachmann KN, Grijalva CG, Rothman RL, Chakkalakal RJ.

Pharmacoepidemiol Drug Saf. 2019 Jan 24. doi: 10.1002/pds.4718. [Epub ahead of print]

PMID:
30680840
11.

Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator.

Vella A, Freeman JLR, Dunn I, Keller K, Buse JB, Valcarce C.

Sci Transl Med. 2019 Jan 16;11(475). pii: eaau3441. doi: 10.1126/scitranslmed.aau3441.

PMID:
30651321
12.

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.

Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP.

Circulation. 2018 Dec 18;138(25):2884-2894. doi: 10.1161/CIRCULATIONAHA.118.034516.

PMID:
30566004
13.

Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes.

Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J, Mastracci TL, Marcovina S, Qian WJ, Yi L, Swensen AC, Yip-Schneider M, Schmidt CM, Considine RV, Arvan P, Greenbaum CJ, Evans-Molina C; T1D Exchange Residual C-peptide Study Group.

Diabetes Care. 2019 Feb;42(2):258-264. doi: 10.2337/dc17-2625. Epub 2018 Dec 10.

PMID:
30530850
14.

Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System.

Wang T, Lu W, Tang H, Buse JB, Stürmer T, Gower EW.

Diabetes Care. 2019 Feb;42(2):e21-e23. doi: 10.2337/dc18-1893. Epub 2018 Dec 7. No abstract available.

PMID:
30530488
15.

Advances in transdermal insulin delivery.

Zhang Y, Yu J, Kahkoska AR, Wang J, Buse JB, Gu Z.

Adv Drug Deliv Rev. 2018 Dec 8. pii: S0169-409X(18)30309-0. doi: 10.1016/j.addr.2018.12.006. [Epub ahead of print] Review.

PMID:
30528729
16.

Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial.

Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, Pratley R, Réa RR, Kerr Saraiva JF, Rasmussen S, Tornøe K, von Scholten BJ, Buse JB; and the LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Ann Intern Med. 2018 Dec 4. doi: 10.7326/M18-1569. [Epub ahead of print] No abstract available.

PMID:
30508430
17.

Health Literacy, Glycemic Control, and Physician-Advised Glucose Self-Monitoring Use in Type 2 Diabetes.

Alvarez PM, Young LA, Mitchell M, Blakeney TG, Buse JB, Vu MB, Weaver MA, Rees J, Grimm K, Donahue KE.

Diabetes Spectr. 2018 Nov;31(4):344-347. doi: 10.2337/ds18-0064.

PMID:
30510390
18.

Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015.

Crowley MJ, Gokhale M, Pate V, Stürmer T, Buse JB.

Diabetes Obes Metab. 2018 Nov 20. doi: 10.1111/dom.13589. [Epub ahead of print]

PMID:
30456843
19.

Liraglutide and Glycaemic Outcomes in the LEADER Trial.

Zinman B, Nauck MA, Bosch-Traberg H, Frimer-Larsen H, Ørsted DD, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Diabetes Ther. 2018 Dec;9(6):2383-2392. doi: 10.1007/s13300-018-0524-z. Epub 2018 Nov 3.

20.

Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.

Mentz RJ, Bethel MA, Merrill P, Lokhnygina Y, Buse JB, Chan JC, Felício JS, Goodman SG, Choi J, Gustavson SM, Iqbal N, Lopes RD, Maggioni AP, Öhman P, Pagidipati NJ, Poulter NR, Ramachandran A, Reicher B, Holman RR, Hernandez AF; EXSCEL Study Group.

J Am Heart Assoc. 2018 Oct 2;7(19):e009304. doi: 10.1161/JAHA.118.009304.

Supplemental Content

Loading ...
Support Center